focus -WSS

focus

author：Wikipedia 2025-08-26 23:44:28 - browse：8673

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Beam Therapeutics to lay off 20% of its staff, re

WSS

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Lawmakers consider Medicare pay reforms for doctors

Senate committee scrutinizes Medicare Advantage brokers

How to improve immunocompromised access to mAb treatments

Lawmakers consider Medicare pay reforms for doctors

Why health workers in Gaza are injured or die at high rates

focus

focus

hotspot

Sports medicine is finally prioritizing gender equality

How to improve immunocompromised access to mAb treatments

Drug repurposing or repositioning? The language matters

Software glitch causes Tandem insulin pump to shutdown, FDA warns

At least 13 dead in Texas as scorching temps continue

Senate committee scrutinizes Medicare Advantage brokers

Anesthesiologist group: stop taking Ozempic before surgery

CDC wastewater surveillance dashboard to track bird flu hotspots

Hepatitis C has a cure — but many Americans still lack access to it

The EU Joint Clinical Assessment needs to live up to its promise

hotspot

Will Ozempic

H5N1 bird flu: what we're starting to learn about infection in cows

Making AI in medicine accessible to smaller, and rural hospitals

2023 STAT Wunderkinds: get to know the winners

After gene therapy, two congenitally deaf children hear for the first time

Senate committee scrutinizes Medicare Advantage brokers

Wikipedia

leisure time

focus

explore